Liquid Immunogenic Fiducial Eluter (LIFE) for Cervical Cancer Treatment

用于宫颈癌治疗的液体免疫原性基准洗脱器 (LIFE)

• 批准号: 10385213
• 负责人: Wilfred Ngwa
• 金额: $ 40万
• 依托单位: NANOCAN THERAPEUTICS CORPORATION
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-05-01 至 2024-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10385213
• 关键词: Affect; African American; Alginates; Animal Cancer Model; Animals; Anti-CD40; Antigen-Presenting Cells; Biocompatible Materials; Brachytherapy; Cancer Model; Cancer Patient; Cells; Clinical; Clinical Trials; Collaborations; Data; Development; Diffuse; Disease; Distant; Dose; Electrons; Ensure; Extravasation; Fractionated radiotherapy; Gel; Goals; Health Services Accessibility; Hematology; Hepatotoxicity; High-Dose Rate Brachytherapy; Histopathology; Hospitals; Hydrogels; Immune; Immunologic Adjuvants; Immunologic Memory; Immunosuppression; Immunotherapeutic agent; Immunotherapy; In Situ; Intervention; Latino Population; Legal patent; Liquid substance; Magnetic Resonance Imaging; Malignant Neoplasms; Malignant neoplasm of cervix uteri; Measurement; Measures; Neoplasm Metastasis; Organ; Patients; Phase; Photons; Population; Radiation therapy; Regimen; Renal function; Resource-limited setting; Risk; Safety; Series; Small Business Technology Transfer Research; Sodium; Survival Rate; Technology; Therapeutic; Time; Toxic effect; Treatment Efficacy; Treatment Protocols; Tumor Volume; Universities; Woman; Work; World Health Organization; X-Ray Computed Tomography; biomaterial compatibility; cancer care; cancer health disparity; cancer therapy; clinical translation; cohort; commercialization; contrast imaging; cost; disease disparity; disparity reduction; effective therapy; image guided; image guided radiation therapy; immunogenic; immunotoxicity; improved; in situ vaccination; innovation; innovative technologies; low and middle-income countries; medical schools; meter; mortality; nano; nanoparticle; neoantigens; neoplasm immunotherapy; new technology; novel strategies; palliation; patient population; patient prognosis; product development; tumor

Project Summary Current treatment options for advanced cervical cancer are limited, with a 5-year overall survival rate of 17%. In the USA, pervasive disparities remain in access to treatment and mortality, disproportionately affecting African American and Latino populations. Innovative therapeutic approaches for metastatic disease that can increase access to care and reduce disparities are greatly needed. To meet this need, in this project, Nanocan Therapeutics Corporation in collaboration with Johns Hopkins University, will develop innovative technology that can extend the use of local radiotherapy (RT) from palliation to distant control of metastatic cervical cancer with substantially reduced treatment time and cost, facilitating access to care and reducing disparities. The new technology, which Nanocan has licensed from Brigham and Women’s Hospital at Harvard Medical School is a Liquid Immunotherapeutic Fiducial Eluter (LIFE) gel that can be easily administered locally and works in conjunction with hypo-fractionated radiotherapy for treatment of patients with advanced cervical cancer. Preliminary studies show that the use of the biocompatible/biodegradable LIFE gel technology can cause regression of both treated (local) and distant untreated/metastatic tumors and enable development of immunologic memory controlling disease for a long time. This Phase 1 STTR project focuses on optimizing efficacy and safety when employing the LIFE gel with HFRT in metastatic cervical cancer models setting. The results will set the stage for the first clinical trial. Innovative advantages of the LIFE gel include major potential to overcome immunosuppression due to sustained delivery, minimal systemic/overlapping toxicities, simple short treatment regimen, and providing imaging contrast for precision RT. The highest clinical impact of the LIFE gel technology approach is anticipated in significantly improved survival of advanced cervical cancer patients. Preliminary studies also show that this can provide a substantially cheaper alternative to systemic treatment and replace the intensive regimens over months to a short intervention, which will create significant opportunities for better global access to cancer care, and reduce cancer disparities.

项目摘要 晚期宫颈癌的当前治疗选择有限，总生存率为5年 17％。在美国，普遍存在的差异仍然不成比例地获得治疗和死亡率 影响非裔美国人和拉丁裔人口。转移性的创新治疗方法 非常需要增加可以增加护理和减少分布的疾病。为了满足这种需求， 在这个项目中，纳米班治疗公司与约翰·霍普金斯大学合作，将 开发可以将局部放射疗法（RT）扩展到距离扩展到遥远的创新技术 控制转移性宫颈癌的治疗时间和成本大大减少，支持 获得护理和减少差异。 Nanocan已从Brigham许可的新技术 哈佛医学院的妇女医院是一所液体免疫治疗基金会（Life） 凝胶可以很容易地在本地给药，并与不相差放射疗法一起使用 用于治疗晚期宫颈癌患者。初步研究表明使用 生物相容性/可生物降解的生命凝胶技术可能会导致经过处理的（本地）和远处的回归 未经治疗/转移性肿瘤以及能够开发免疫记忆控制疾病 很久。该第1阶段的STTR项目着重于在运用生活时优化效率和安全性 在转移性宫颈癌模型的设置中，用HFRT凝胶。结果将为第一个设定舞台 临床试验。生命凝胶的创新优势包括克服的主要潜力 免疫抑制是由于持续交付，最小的全身性/重叠毒性而引起的，简单的简短 治疗方案，并为精度RT提供成像对比度。最高的临床影响 预计生命凝胶技术方法将在高级宫颈癌的生存中显着改善 患者。初步研究还表明，这可以提供次要的替代品 全身治疗并将密集型疗法替换为几个月的简短干预措施，这将 为更好的全球获得癌症护理而创造了很大的机会，并减少癌症分布。